Graduated in Molecular Cellular and Developmental Biology - University of Colorado (1987) and PhD in Immunology and Microbiology - University of Colorado Medical Center (1992), postdoctoral at DNAX Research Institute (1991-94), Visiting Associate Professor Stanford Univeristy (2006- 2007), and Visiting Researcher National Institutes of Health- National Cancer Institute (2021-current). He currently leads the Translational Immuno-oncology Laboratory, Hospital Israelita Albert Einstein and Director of the Center for Research in Immuno-oncology (CRIO). He works with applied research to understand the interaction of cancer with the immune system and the pathogen-host interaction, aimed at developing new therapies, diagnostics and biomarkers of disease progression. Using a range of multi-omics approaches, including multiparameter flow cytometry, scRNAseq, IBEX, exome and transcriptome, we focus on immunoregulation research in cancer and human infectious diseases. (Source: Lattes Curriculum)
| Articles published in Pesquisa para Inovação FAPESP about the researcher: |
| FAPESP launches Engineering Research Centers with Embraer, Ericsson and GSK |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Immune based therapeutics such as checkpoint inhibitors have proven to work across several cancer types and the potential impact novel immuno-oncology targets can have on inducing anti-cancer responses, either as standalone, or as combination/adjuvant therapies is great. Thus, our central overriding scientific focus is to discover and validate immunoregulatory targets with the potential t…
There is still a significant portion of gynaecological cancer patients that do not respond well to immune-based cancer therapies. Results of a phase II clinical trial demonstrated the efficacy of the PD-1 inhibitor in advanced cervical cancer which led to Food and Drug Administration (FDA) approval. However, 5-year relative survival for these patients is still less than 20%. In ovarian ca…
Currently, intraoperative diagnosis is performed by histopathological freezing and allows differentiation between tissue types, and the diagnosis of benign and malignant diseases, but there are still a number of factors that contribute to indeterminate or incorrect results in this technique. The MasSpec Pen is a mass spectrometry-based device that allows real-time identification of biomol…
(Only some records are available in English at this moment)
There is still a significant portion of gynaecological cancer patients that do not respond well to immune-based cancer therapies. Results of a phase II clinical trial demonstrated the efficacy of the PD-1 inhibitor in advanced cervical cancer which led to Food and Drug Administration (FDA) approval. However, 5-year relative survival for these patients is still less than 20%. In ovarian ca…
(Only some records are available in English at this moment)
The triple negative breast cancer (TNBC) is an aggressive breast cancer subtype. The conventional treatment is based on chemotherapy followed by surgery, leading 50% of patients to achieve complete recovery, while patients who do not respond present a high mortality rate. A combined treatment with pembrolizumab (anti-PD-1) in TNBC allow an improvement in clinical outcome. In recent years,…
| 1 / 1 | Ongoing research grants |
| 9 / 9 | Ongoing scholarships in Brazil |
| 8 / 8 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 19 / 19 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID